Shares of iKena Oncology are up 12% after announcing discontinuation of the clinical IK-930 program, the company’s TEAD1- selective Hippo pathway inhibitor and continued clinical development of IK-595. The company also noted that it is executing a workforce reduction of approximately 53%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IKNA: